Sparrow Pharmaceuticals Begins Phase 2 Study for ACS Treatment

Sparrow Pharmaceuticals Begins Phase 2 Study for ACS Treatment

By Daniella Parra Sparrow Pharmaceuticals said it initiated a Phase 2 ACSpire study for SPI-62, a potent HSD-1 inhibitor, targeting autonomous cortisol secretion (ACS). ACS results from excessive cortisol production due to benign adrenal tumors and can lead to severe...

Apollomics Treating MET-Altered Cancers: KUNPENG Trial Results

Apollomics Treating MET-Altered Cancers: KUNPENG Trial Results

By Daniella Parra Apollomics Inc. (Nasdaq: APLM) unveiled results from the KUNPENG clinical trial at ESMO 2023, showing vebreltinib’s potential as a treatment for cancers with MET alterations, they said. The Phase 2 trial by Apollomics’ partner, Avistone Biotechnology Ltd.,...

Input your search keywords and press Enter.